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We describe the case of a patient with long-standing Parkinson’s disease and recurrent bilateral pleural eﬀusions. The pleural fluid
was an exudate, rich in normal lymphocytes, and the echocardiogram, chest computerized axial tomography, and immunological,
microbiological and cytological studies were negative. The patient had been taking bromocriptine, which can be related to chronic
pleural eﬀusions. Using Pubmed, we found about 40 cases of pleuropulmonary changes or constrictive pericarditis that were
related to bromocriptine. We decided to suspend this drug, with resolution of the pleural eﬀusion and respiratory complaints for
more than a year now. We discuss possible underlining mechanisms for this and emphasize the importance of collecting the past
medical history and medication and of considering possible iatrogenic eﬀects.
1. Case Report
A 75-year-old male, with long-standing Parkinson’s disease
and benign prostatic hyperplasia, was brought into the
emergency department after syncope. He had felt dyspnea,
but denied any other prodromal symptoms and did not have
involuntary movements or urinary or fecal incontinence.
He did not have any other chronic diseases, habits,
or allergies, and his medications were levodopa/carbidopa
250/25mg qid, bromocriptine 30mg daily, amantadine
100mg bid, alprazolam 2.5mg daily, and tamsulosin 0.4mg
daily.
He had been admitted to the hospital 3 times during
the last 4 months with bilateral recurrent pleural eﬀusions,
dyspnea, and episodes of noncardiogenic acute pulmonary
edema of unknown etiology.
When he was admitted, he referred to dyspnea and
pleuritic chest pain. The physical examination showed signs
of respiratory distress, oxygen saturation was 88% in room
air, and the vital signs were within normal limits, without
jugular venous distension or edema. Heart sounds were
normal, without murmurs, and he had no audible breath
sounds on the lower half of the right lung and lower third
of the left lung field, without crackles, wheezing, or rhonchi
bilaterally.
The chest X-ray confirmed a big pleural eﬀusion on the
right side and a moderate one on the left (Figure 1). The
pleural eﬀusion on the right-hand side was drained and
was found to be an exudate, rich in normal lymphocytes,
with normal values of adenosine deaminase activity and
no neoplastic cells. The pleural biopsy revealed fibrosis and
moderate inflammatory infiltrate with lymphocytes, plas-
mocytes, and neutrophils, without granulomas, neoplastic
cells, or amyloid; the bacterial cultures and polymerase chain
reaction for M. tuberculosis were negative.
The complete blood count, liver enzymes, creatinine,
ionogram, brain (BNP natriuretic peptide), and hormone
(thyroid-stimulating TSH) were normal and only the ery-
throcyte sedimentation rate was elevated. Blood cultures
and urinalysis were negative. The PPD test (purified protein
derivative) was negative (3mm). The peripheral blood flow
cytometry showed only an augmentation of NK cells, sugges-
tive of cell activation. The transthoracic echocardiogram and
EKG showed no relevant changes. The analysis of the 24-hour
Holter and a 2-week electrocardiographic event recorder
showed only one short episode of supraventricular tachycar-
dia. The immunological study revealed only positive antin-
uclear antibodies (1/160), with immunoglobulins, comple-
ment, rheumatoid factor, antidouble stranded DNA anti-
bodies, and antineutrophil cytoplasmic antibodies within
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Figure 1: Chest X-ray on the day of admission.
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Figure 2: Chest computerized axial tomography shortly after the
admission in the hospital.
normal values. The electroimmunoassays and detection of
serum-free light chains were negative. A computerized axial
tomography scan of the thorax, abdomen, and pelvis did not
reveal any important changes either, with the exception of the
pleural eﬀusion and pleural thickening (Figure 2).
This case was very intriguing, because there was no
apparent cause for the chronic exudative lymphocytic bilat-
eral pleural eﬀusions and for the episodes of pulmonary
edema without heart or lung diseases.
We then decided to investigate the drugs that the patient
was taking and found out that bromocriptine and other
classic ergolines, such as methysergide and ergotamine, had
been linked to chronic pleural eﬀusions, generally exudates,
and pleuropulmonary fibrosis.
After failure of other treatments and drainages in avoid-
ing recurrence of the pleural eﬀusion, we decided to stop the
bromocriptine.
Within less than a month, the considerable bilateral
pleural eﬀusion disappeared (Figure 3), and the patient
did not have recurrence of the pleural eﬀusions or acute
pulmonary oedema episodes since then, for more than a year
now.
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Figure 3: Chest X-ray one month after suspending the bromocrip-
tine.
2. Discussion
Pleuropulmonary changes are rare events that have been
related to bromocriptine. This association was first pointed
out 30 years ago [1], but very few cases have been reported.
In a review of the literature, using PubMed with the
keywords “bromocriptine” and “pleural eﬀusion”/“pleu-
ropulmonary”/“pericarditis,” only about 40 cases of pleural
eﬀusions and about 4 of constrictive pericarditis were
found. We did not take into account the cases where other
possible confounding factors were involved, namely, asbestos
exposure.
The pleural eﬀusions related to bromocriptine are usually
bilateral, exudative, rich in lymphocytes, and with fibrotic
changes [2]. These changes could appear only years after
starting to take the drug.
Elevated erythrocyte sedimentation rate and an inflam-
matory syndrome [3], as well as positive antinuclear anti-
bodies, both seen in this patient, were also verified in other
cases. Curiously, a large majority of the patients were male,
over 60 years old, presenting with paroxysmal chest pain
and dyspnea. Most of them had pleural thickening and
pleural eﬀusions [4–7], usually bilateral or on the right side,
but some also had pulmonary interstitial infiltrates [8] and
restrictive ventilatory changes [6]. Constrictive pericarditis,
in some cases with associated pleural eﬀusion, has also been
described [9–11].
In some countries, the drug information that comes
with bromocriptine already says that, in high doses and
prolonged use, bromocriptine can cause pleural eﬀusions
and that, in patients presenting with pleuropulmonary signs
or symptoms, the interruption of the drug should be
considered, even though a clear causal eﬀect was not found.
Some brands even advise patients to do an echocardiogram,
as well as a check up of the lungs, heart, and kidney function,
before beginning treatment.
There are a couple of mechanisms evoked to explain
these side eﬀects: immunologic, causing a hypersensitivity
response; vasoconstrictive, being a serotonin-like substance
and capable of inducing fibrosis; a direct toxic fibrogenesis
eﬀect.
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However, the physiopathology of these serosal changes is
not clear yet. Nevertheless, the suspension of bromocriptine
was eﬀective in this patient, as in the other described
cases, and we may also speculate that the episodes of non
cardiogenic pulmonary oedema could also be linked with
bromocriptine pleuropulmonary changes.
Therefore, the suspension of the drug is worth trying
in patients presenting with chronic pleural eﬀusions, after
excluding other causes.
This case also reminds us of the importance of the past
medical history in the diagnosis rationale and of always
considering possible side eﬀects of the medication.
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